Skandinaviska Enskilda Banken AB publ Has $6.62 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Skandinaviska Enskilda Banken AB publ lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 39.3% in the third quarter, HoldingsChannel reports. The firm owned 335,500 shares of the biopharmaceutical company’s stock after selling 217,200 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Catalyst Pharmaceuticals were worth $6,616,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CPRX. Federated Hermes Inc. raised its position in Catalyst Pharmaceuticals by 52.8% in the 3rd quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company’s stock worth $7,669,000 after purchasing an additional 134,509 shares during the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of Catalyst Pharmaceuticals by 1,216.5% during the third quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company’s stock worth $3,260,000 after acquiring an additional 152,925 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Catalyst Pharmaceuticals by 3,559.0% during the third quarter. Exchange Traded Concepts LLC now owns 62,971 shares of the biopharmaceutical company’s stock worth $1,241,000 after acquiring an additional 61,250 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Catalyst Pharmaceuticals by 957.5% during the third quarter. SG Americas Securities LLC now owns 83,690 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 75,776 shares during the period. Finally, Cresset Asset Management LLC boosted its holdings in Catalyst Pharmaceuticals by 588.1% in the second quarter. Cresset Asset Management LLC now owns 87,418 shares of the biopharmaceutical company’s stock valued at $1,897,000 after acquiring an additional 74,713 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on CPRX shares. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Finally, Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $33.20.

Catalyst Pharmaceuticals Trading Up 0.5%

Shares of Catalyst Pharmaceuticals stock opened at $24.42 on Friday. The stock’s fifty day simple moving average is $23.82 and its 200 day simple moving average is $22.06. The company has a market capitalization of $3.00 billion, a PE ratio of 14.20, a PEG ratio of 0.81 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Carmen Jeffrey Del sold 10,983 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $23.33, for a total transaction of $256,233.39. Following the transaction, the insider owned 3,962 shares in the company, valued at $92,433.46. The trade was a 73.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Molly Harper sold 26,746 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the completion of the transaction, the director owned 2,360 shares of the company’s stock, valued at $54,870. This represents a 91.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).